Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/EyePoint, Inc./ 144

Notice of Proposed Sale · 144

EyePoint, Inc.

EYPTNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Jul 21, 2026Accepted Jul 21, 2026, 4:44 PM EDTFiling CIK 1450485Accession 0001959173-26-005309
View company →Permanent SEC source ↗
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
EyePoint, Inc.
Issuer CIK
0001314102
SEC file number
000-51122
Phone
617-926-5000
Person for whose account securities are to be sold
Lurker Nancy
Relationships to issuer
Officer
Street
480 PLEASANT STREET
Street (continued)
SUITE C400
City
WATERTOWN
State / country code
MA
Postal code
02472

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common421,2355,497,116.7583,841,29807/21/2026NASDAQFidelity Brokerage Services

Broker / market maker — proposed row 1, entry 1

Name
Fidelity Brokerage Services
Street
245 SUMMER STREET
City
Boston
State / country code
MA
Postal code
02110

Acquisition of securities to be sold

Acquisition of securities to be sold · 24 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common01/06/2026Stock OptionsEYPT75,133N01/06/2026Compensation
Common01/05/2026Stock OptionsEYPT12,666N01/05/2026Compensation
Common07/10/2025Stock OptionsEYPT11,111N07/10/2025Compensation
Common02/09/2025Stock OptionsEYPT20,000N02/09/2025Compensation
Common01/06/2025Stock OptionsEYPT75,134N01/06/2025Compensation
Common01/05/2025Stock OptionsEYPT12,667N01/05/2025Compensation
Common08/16/2024Stock OptionsEYPT3,173N08/16/2024Compensation
Common07/10/2024Stock OptionsEYPT11,111N07/10/2024Compensation
Common01/31/2023Stock OptionsEYPT2,745N01/31/2023Compensation
Common02/21/2022Stock OptionsEYPT11,508N02/21/2022Compensation
Common02/09/2022Stock OptionsEYPT17,533N02/09/2022Compensation
Common01/31/2022Stock OptionsEYPT3,019N01/31/2022Compensation
Common06/14/2021Stock OptionsEYPT4,500N06/14/2021Compensation
Common02/28/2021Stock OptionsEYPT12,467N02/28/2021Compensation
Common02/21/2021Stock OptionsEYPT3,717N02/21/2021Compensation
Common01/29/2021Stock OptionsEYPT3,541N01/29/2021Compensation
Common07/31/2020Stock OptionsEYPT878N07/31/2020Compensation
Common06/30/2020Stock OptionsEYPT12,466N06/30/2020Compensation
Common06/27/2020Stock OptionsEYPT977N06/27/2020Compensation
Common02/09/2024Stock OptionsEYPT22,591N02/09/2024Compensation
Common01/06/2024Stock OptionsEYPT52,090N01/06/2024Compensation
Common02/09/2023Stock OptionsEYPT37,533N02/09/2023Compensation
Common02/28/2022Stock OptionsEYPT12,466N02/28/2022Compensation
Common02/21/2022Stock OptionsEYPT2,209N02/21/2022Compensation

Prior-sale reporting

Nothing to report for the preceding three months
Y

Remarks

294,346 shares are being sold from Nancy luker individually 126,889 shares are being sold from THE NANCY S LURKER 2020 IRRVOCABLE TRUST

Notice signature

Notice date
07/21/2026
Signed
Jason Coleman as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Lurker Nancy

Company context

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

Current securities

EYPTNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
  2. Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
  3. Other EventsOct 19, 2026
  4. SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Oct 7, 2026
  5. Other EventsSep 10, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.